Cutaneous Squamous Cell Carcinoma: Updates in Staging and Management

Thomas S Bander; Kishwer S Nehal; Erica H Lee

doi:10.1016/j.det.2019.03.009

Cutaneous Squamous Cell Carcinoma: Updates in Staging and Management

Dermatol Clin. 2019 Jul;37(3):241-251. doi: 10.1016/j.det.2019.03.009.

Authors

Thomas S Bander¹, Kishwer S Nehal¹, Erica H Lee²

Affiliations

¹ Memorial Sloan Kettering Cancer Center, 16 East 60th Street, New York, NY 10022, USA.
² Memorial Sloan Kettering Cancer Center, 16 East 60th Street, New York, NY 10022, USA. Electronic address: leee@mskcc.org.

PMID: 31084718
DOI: 10.1016/j.det.2019.03.009

Abstract

Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the United States. Outcomes are generally favorable, but a subset of cSCC is biologically distinct and requires a different approach because of its higher risk of local recurrence, metastasis, and death. This article focuses on the recent literature regarding identification of this high-risk subset, efforts to validate and improve the prognostic ability of staging systems, and updates in management.

Keywords: AJCC staging; Cutaneous squamous cell carcinoma; EGFR inhibitor; High-risk skin cancer; PD-1 inhibitor; Sentinel lymph node biopsy; Skin cancer radiologic imaging; Squamous cell carcinoma staging.

Publication types

Review

MeSH terms

Carcinoma, Squamous Cell / secondary*
Carcinoma, Squamous Cell / therapy*
Diagnostic Imaging
Humans
Lymphatic Metastasis
Neoplasm Staging*
Prognosis
Risk Assessment
Skin Neoplasms / pathology*
Skin Neoplasms / therapy*